J 2016

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015

ASTERMARK, Jan; Dan HART; Sébastien LOBET; Jan BLATNÝ; Roseline D´OIRON et al.

Základní údaje

Originální název

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015

Autoři

ASTERMARK, Jan; Dan HART; Sébastien LOBET; Jan BLATNÝ; Roseline D´OIRON; Gili KENET; Gerry DOLAN; Valérie LIBOTTE a Cedric HERMANS

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2016, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.653

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00093441

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

RECOMBINANT FACTOR-VIII; DOSE SECONDARY PROPHYLAXIS; ON-DEMAND TREATMENT; FC FUSION PROTEIN; INHIBITOR DEVELOPMENT; PHYSICAL-ACTIVITY; RISK-FACTORS; A PATIENTS; FACTOR-IX; RHEUMATOID-ARTHRITIS

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2017 10:15, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The 6(th) Haemophilia Global Summit was held in Prague, Czech Republic, in September 2015. The programme was designed by an independent Scientific Steering Committee of haemophilia experts and aimed to share optimal management strategies for haemophilia at all life stages, explore recent potential advances in the management of haemophilia A and B and discuss challenges in haemophilia care. In this supplement from the meeting, Dan Hart reviews the lessons that can be learnt from cost-constrained environments with regard to improving care for people with haemophilia globally. Sebastien Lobet discusses the importance of physical activity for optimising care and Roseline d'Oiron and Jan Blatny consider the role of real-world data in understanding the effect of treatment in a clinical setting over the long term and the true impact of treatment on the day-to-day life of the patient. Gili Kenet addresses the current challenges relating to the optimal management of prophylaxis, and Gerry Dolan and Cedric Hermans discuss the value of pharmacokinetic (PK) parameters in informing treatment decisions. Cedric Hermans and Valerie Libotte explore the importance of considering social and occupational development factors as an integral part of haemophilia care, and Jan Astermark reviews key strategies to predict and prevent inhibitor development.